1. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37(4):412-20.
   
   
2. Yoo KJ, Kim HO, Kwak YL, Kang SM, Jang YS, Lim SH, Hwang KC, Cho SW, Yang YS, Li RK, Kim BS. Autologous bone marrow cell transplantation combined with off-pump coronary artery bypass grafting in patients with ischemic cardiomyopathy. Can J
   Surg. 2008 Aug;51(4):269-75.
   
   
3. Yao K, Huang R, Qian J, Cui J, Ge L, Li Y, Zhang F, Shi H, Huang D, Zhang S,Sun A, Zou Y, Ge J.Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart. 2008;94(9):1147-53.
   
   
4. Nasseri BA, Kukucka M, Dandel M, Knosalla C, Potapov E, Lehmkuhl HB, Meyer R, Ebell W, Stamm C, Hetzer R. Intramyocardial delivery of bone marrow mononuclear cells and mechanical assist device implantation in patients with end-stage cardiomyopathy. Cell Transplant. 2007;16(9):941-9.
   
   
5. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A,Liebold A, Nienaber C, Zurakowski D, Freund M, Steinhoff G.Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypassgrafting for chronic ischemic heart disease safety and efficacy studies.The Journal of thoracic and cardiovascular surgery. 2007;133(3):717-25
   

　

Publication/Presentations on heart disease - by NCRM and collaborators